Stay updated on Evobrutinib Study in RMS Patients Clinical Trial
Sign up to get notified when there's something new on the Evobrutinib Study in RMS Patients Clinical Trial page.

Latest updates to the Evobrutinib Study in RMS Patients Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record for the evobrutinib study in participants with relapsing multiple sclerosis is displayed, with study details, results measures, eligibility criteria, and supporting documents. It notes that the Phase 3 trial was terminated early and is no longer recruiting.SummaryDifference59%

- Check16 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check23 days agoChange DetectedAn NIH banner announces that federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer identifies the site revision as v3.7.1 instead of v3.7.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe NCT04032171 study page now renders a 403 Forbidden error, replacing the usual study record content. This change blocks access to the study details and related navigation, signaling restricted visibility of the page.SummaryDifference20%

Stay in the know with updates to Evobrutinib Study in RMS Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Evobrutinib Study in RMS Patients Clinical Trial page.